Kodiak Sciences Inc. (KOD) experienced a dramatic stock surge of nearly 178% on September 28, 2026, after it released positive Phase 3 trial data for its eye treatments targeting wet age-related macular degeneration. The stock traded 38.46 million shares that day, significantly exceeding its average volume of about 701,000 shares. This surge contributed to KOD’s impressive growth of over 300% within the year, rising from approximately $22 in February to over $98 currently.
As the biotech sector faces increasing volatility, veteran trader Jonathan Rose emphasizes the importance of closely monitoring FDA decision dates through the Prescription Drug User Fee Act (PDUFA) calendar. Upcoming PDUFA dates could influence other biotech stocks and potentially lead to significant price movements. Noteworthy companies under observation include BioMarin Pharmaceutical Inc. (BMRN), Precigen (PGEN), and Absci Corp. (ABSI), which are associated with promising advancements and regulatory milestones.
Jonathan Rose advises traders to exercise caution and follow disciplined trading strategies, especially in a market characterized by sharp price changes. He highlights that finding the right stock is just one aspect of trading—knowing when and whether to enter a position is equally crucial for success.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
